Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

4.3. Results ............................................ 59
4.4. Conclusion ......................................... 68
4.5. Recommendations and future work ...................... 69
References to Chapter 4 ........................................ 69
CHAPTER 5.
PRECLINICAL EVALUATION OF
90 Y LABELLED RITUXIMAB AND ERIC-1:
TWO ANTIBODIES FOR TUMOUR THERAPY ...... 70
K. Schomäcker, T. Fischer
5.1. Experiments ........................................ 71
References to Chapter 5 ........................................ 81
CHAPTER 6.
DEVELOPMENT OF RADIOPHARMACEUTICALS
BASED ON 188 Re AND 90 Y FOR RADIONUCLIDE
THERAPY AT BARC ............................ 82
U. Pandey, M. Kameswaran, S. Subramanian,
R. Chakravarty, H.D. Sarma, G. Samuel,
A. Dash, M. Venkatesh, M.R.A. Pillai
6.1. Validation of the EPC technique for determination of
90 Sr contamination in 90 Y eluted from
90 Sr/ 90 Y generator systems ............................. 82
6.2. Preparation and bioevaluation studies of
90 Y labelled rituximab and TheraCIM antibodies ............ 87
6.3. Yttrium-90 radiopharmaceuticals for liver cancer ........... 99
References to Chapter 6 ........................................ 105
CHAPTER 7.
DEVELOPMENT OF THERAPEUTIC
RADIOPHARMACEUTICALS BASED ON
90 Y BIOTIN .................................... 107
L. Garaboldi, M. Chinol
7.1. Introduction ........................................ 107
7.2. Materials and methods ................................ 109
7.3. Results ............................................ 112